Acquisition Announced
Sun Pharmaceutical Industries acquisition of Organon & Co.
US$12bn enterprise value
Announced 26 Apr 2026 · NYSE: OGN · US$14.00 cash per share
Advisers
Organon & Co.
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Sun Pharmaceutical Industries
Acquirer
- Financial adviser
- Legal adviser
- Target
- Organon & Co.
- Acquirer
- Sun Pharmaceutical Industries
- Target based in
- United States
- Buyer based in
- India
- Sector
- Pharma
In the league tables
Similar deals
- CVC GBL acquisition of Recordati S.p.A. May 2026 · US$13bn · Pharma
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Curium US Holdings acquisition of Lantheus Holdings Aug 2026 · US$8bn · Radiopharmaceuticals
- Eli Lilly and Company acquisition of Centessa Pharmaceuticals Mar 2026 · US$6.3bn · Biotech
- Biogen acquisition of Apellis Pharmaceuticals Mar 2026 · US$5.6bn · Biotech
Sources
- Apr 2026 Jefferies: Joint Financial Advisor: Acquisition of Organon jefferies.com
- 27 Apr 2026 Press release (EX-99.1, exhibit), Sun Pharma signs Definitive Agreement to Acquire Organon sec.gov
- 28 Apr 2026 S&C Advises Organon on Acquisition by Sun Pharma sullcrom.com
- 17 Jun 2026 Definitive merger proxy statement (DEFM14A), Organon & Co. sec.gov





